Skip to main content
TipRanks
Go Ultimate75% OFF

Kairos Pharma, Ltd. (KAPA) Stock Statistics & Valuation Metrics

180 Followers

Total Valuation

Kairos Pharma, Ltd. has a market cap or net worth of $1.54M. The enterprise value is $6.11T.

Market Cap
$1.54M
Enterprise Value
$6.11T

Share Statistics

Kairos Pharma, Ltd. has 3,385,383 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
3,385,383
Owned by Insiders
32.08%
Owned by Institutions
1.55%

Financial Efficiency

Kairos Pharma, Ltd.’s return on equity (ROE) is -0.86 and return on invested capital (ROIC) is -87.87%.

Return on Equity (ROE)
-0.86
Return on Assets (ROA)
-0.83
Return on Invested Capital (ROIC)
-87.87%
Return on Capital Employed (ROCE)
-0.88
Revenue Per Employee
0
Profits Per Employee
-1.36M
Employee Count
4
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Kairos Pharma, Ltd. is -0.22. Kairos Pharma, Ltd.’s PEG ratio is -0.07.

PE Ratio
-0.22
PS Ratio
0.00
PB Ratio
0.39
Price to FCF
-0.37
Price to Operating Cash Flow
-0.37
PEG Ratio
-0.07

Income Statement

In the last 12 months, Kairos Pharma, Ltd. had revenue of 0 and earned -5.45M in profits. Earnings per share was -2.10.

Revenue
0
Gross Profit
0
Operating Income
-5.57M
Pretax Income
-5.45M
Net Income
-5.45M
EBITDA
-5.29M
Earnings Per Share (EPS)
-2.10

Cash Flow

In the last 12 months, operating cash flow was -4.11M and capital expenditures 0, giving a free cash flow of -4.11M billion.

Operating Cash Flow
-4.11M
Free Cash Flow
-4.11M
Free Cash Flow per Share
-1.23

Dividends & Yields

Kairos Pharma, Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-267.71%
Earnings Yield
-420.69%

Stock Price Statistics

Beta
1.41
52-Week Price Change
-91.82%
50-Day Moving Average
1.08
200-Day Moving Average
2.76
Relative Strength Index (RSI)
27.35
Average Volume (3m)
364.48K

Financial Position

Kairos Pharma, Ltd. as a current ratio of 27.07, with Debt / Equity ratio of 0.00%

Current Ratio
27.07
Quick Ratio
27.07
Debt to Market Cap
0.00
Net Debt to EBITDA
0.85
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Kairos Pharma, Ltd. has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Kairos Pharma, Ltd. EV to EBITDA ratio is 0.25, with an EV/FCF ratio of 0.39.

EV to Sales
0.00
EV to EBITDA
0.25
EV to Free Cash Flow
0.39
EV to Operating Cash Flow
0.39

Balance Sheet

Kairos Pharma, Ltd. has $3.13M in cash and marketable securities with $0.00 in debt, giving a net cash position of $3.13M billion.

Cash & Marketable Securities
$3.13M
Total Debt
$0.00
Net Cash
$3.13M
Net Cash Per Share
$0.92
Tangible Book Value Per Share
$1.16

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Kairos Pharma, Ltd. is $12.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$12.00
Price Target Upside
2549.01% Upside
Analyst Consensus
Moderate Buy
Analyst Count
1
Revenue Growth Forecast
―
EPS Growth Forecast
30.88%